China and Hong Kong patent boost for Sareum
Cambridge UK life science business Sareum has earned significant patent approvals for a key technology in China and Hong Kong.
Under CEO Tim Mitchell, Sareum is beginning to get into its global stride as a specialist cancer drug discovery and development business.
Mitchell (pictured) had previously revealed that the AIM-quoted company was granted similar patents in the US and Europe last September and that other major territories, including Japan, are expected to follow in due course.
The China and Hong Kong patents cover inventions associated with Sareum's Aurora+FLT3 Kinase Inhibitor Programme.
These patents describe compounds that inhibit the activity of Aurora and FLT3 kinase enzymes and the medical use of these compounds, particularly in the treatment of cancer.
Sareum's Aurora+FLT3 inhibitor programme targets acute myeloid leukaemia (AML) and other leukaemias and lymphomas. In disease models of AML, the preclinical development candidate molecule demonstrates greater than 98 per cent tumour inhibition, according to the company.
Preclinical development studies to obtain approval for human clinical trials are being undertaken in collaboration with, and funded by, Hebei Medical University Biomedical Engineering Center (HMUBEC) in China.
Sareum CSO, Dr John Reader, said: “These notifications of patent grants for Sareum in China and Hong Kong demonstrate the strength of intellectual property protecting our Aurora+FLT3 programme and reinforces the patent position for HMUBEC, our development partner in China.”